ストックスクリーナーアプリを入手
1,251.61
3.55%
42.87
アフターアワーズ：
1253.70
2.09
+0.17%
前日終値:
$1,208.74
開ける：
$1235.04
24時間の取引高:
3.73M
Relative Volume:
1.63
時価総額：
$1.12T
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
45.05
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
+7.01%
1か月 パフォーマンス:
+10.17%
6か月 パフォーマンス:
+38.29%
1年 パフォーマンス:
+51.42%
1日の値動き範囲:
$1,230.66
$1,275.88
1週間の範囲:
$1,158.40
$1,275.88
52週間の値動き範囲:
$783.85
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,251.61 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.28 | 610.38B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
283.40 | 500.80B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.19 | 358.21B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.38 | 285.83B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-15 | アップグレード | Berenberg | Hold → Buy |
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
5 Stocks to Start With if You Only Have $1,000 - The Motley Fool
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% - The Motley Fool
Eli Lilly and Co Stock (LLY) Opened Up by 3.70% on Oct 14: Key Drivers Unveiled - TradingKey
Eli Lilly schedules October 29 earnings as Eli Lilly stock sits 4.73 percent below its high - ad-hoc-news.de
4 High-Risk Stocks Built for Big Returns - The Motley Fool
A Look at Eli Lilly and Co (LLY) After 1.4% Decline -- GF Value $1575.10 vs Price $1166.51 - GuruFocus
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's Why Eli Lilly (LLY) Fell More Than Broader Market - Zacks Investment Research
Eli Lilly & Co. stock outperforms competitors despite losses on the day - MarketWatch
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years - The Motley Fool
BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades (XLV:NYSEARCA) - Seeking Alpha
AbbVie, Eli Lilly among mega-cap healthcare stocks with A+ profitability grades - TradingView
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar? - Zacks Investment Research
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. - The Motley Fool
Lilly Begins On $6.5B Houston Manufacturing Facility : CEG - Construction Equipment Guide
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Lilly seeks to provide $19.3M to Lebanon for expanded hazmat services - Inside INdiana Business
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
4 Healthcare Stocks Worth Owning for the Next Decade - The Motley Fool
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. - The Motley Fool
Eli Lilly presented new trial data. Eli Lilly stock gains 1.09 percent - ad-hoc-news.de
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next. - The Motley Fool
Eli Lilly says combining Taltz and Zepbound works better than Taltz alone in psoriasis study - MedWatch
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH? - The Motley Fool
Eli Lilly Sued Over Alleged Digestive Complications From GLP-1 Medication - InkFreeNews.com
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze - The Motley Fool
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Legend Biotech (LEGN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO - Bloomberg.com
Eli Lilly Lobs 4 Suits Alleging Illegal Weight Loss Drug Sales - Law360
Eli Lilly Says Weight Clinic 'Mocks' FDA With Illegal Drugs - Law360
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Zacks Investment Research
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock - Yahoo Finance
3 Top-Ranked Healthcare Mutual Funds for a Defensive Portfolio - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Eli Lilly & Co (LLY) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. - The Motley Fool
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity - Inside INdiana Business
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
Lilly Eli Co (LLY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT, INC. | Shareholder |
Oct 07 '26 |
Proposed Sale |
1,157.49 |
300,000 |
347,247,000 |
0 |
| Jonsson Patrik | EVP & President, LLY Int'l |
Aug 17 '26 |
Sale |
1,175.10 |
6,500 |
7,638,150 |
54,147 |
| Patrik Jonsson | Officer |
Aug 17 '26 |
Proposed Sale |
1,175.10 |
6,500 |
7,638,150 |
0 |
| DONALD ZAKROWSKI | Officer |
Aug 10 '26 |
Proposed Sale |
1,185.71 |
2,000 |
2,371,420 |
0 |
| Zakrowski Donald A | SVP, Finance, & CAO |
Aug 10 '26 |
Sale |
1,185.01 |
2,000 |
2,370,020 |
1,526 |
| Hakim Anat | EVP, GC & Secretary |
Aug 07 '26 |
Sale |
1,190.00 |
5,000 |
5,950,000 |
11,875 |
| Hakim Anat | Officer |
Aug 07 '26 |
Proposed Sale |
1,190.00 |
10,000 |
11,900,000 |
0 |
| Seymour Melissa | EVP, Global Quality |
Aug 01 '26 |
Option Exercise |
0.00 |
981 |
0 |
1,506 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jul 07 '26 |
Proposed Sale |
1,200.06 |
310,000 |
372,018,600 |
0 |
| LILLY ENDOWMENT, INC. | Shareholder |
Jun 26 '26 |
Proposed Sale |
1,127.69 |
305,000 |
343,945,450 |
0 |
0.25%
2.38%
大文字化:
|
ボリューム (24 時間):